Establishment of a Human Acute Promyelocytic Leukemia-Ascites Model in SCID Mice


Acute promyelocytic leukemia (APL) is an interesting model for cancer research because of the presence of the specific PML-RARα fusion gene associated with the clinical response to retinoic acid differentiation therapy. To better understand and improve differentiation induction with retinoic acid, we have established a human APL-ascites model in SCID mice using the NB4 human APL cell line. NB4 (1 x 10⁶ cells) were transplanted into the peritoneum (IP) of SCID mice for 1 month. NB4 ascites cells (A-NB4) appeared, which were then engrafted in SCID mice periodically for 18 passages at an interval of 3 to 4 weeks with a 100% success rate of tumor induction. The mean survival times of SCID mice transplanted with 1 x 10⁶ A-NB4 cells was 21.6 ± 2.3 days. Analysis of the biologic characteristics of ninth passage NB4 ascitic cells was performed and they were found to have the unique response to the differentiation inducer, all-trans retinoic acid (ATRA). Although clinical treatment with ATRA results in a high rate of complete remission (CR), we are still at the beginning of understanding the pathogenesis of APL and the mechanisms underlying ATRA-induced differentiation. In addition, most patients treated with ATRA alone after CR will develop early clinical relapse or require intensive chemotherapy to prevent relapse. To this end, an appropriate and stable animal model of APL is important to study these issues and to measure the in vivo differentiation effect of drugs including ATRA. The availability of NB4 cells (a human APL cell line with t(15;17) and PML-RARα protein) prompted us to explore the possibility of establishing an in vivo model for human APL using these cells.

Severe combined immunodeficiency (SCID) mice lacking functional B and T lymphocytes provide a model for studying the biology of human normal or malignant tissue transplants that do not grow in nude mice, and for evaluating the efficacy of drugs on these tissues. It has been shown that normal myeloid or leukemic cells can grow in SCID mice. In recent years, cells from some human malignant hemopathies, such as acute lymphocytic leukemia, acute granulocytic leukemia (FAB-M1, -M2, -M4, and -M5), and multiple myeloma have been successfully engrafted in SCID mice, opening new prospects for the study of basic mechanisms and treatment of human hematologic diseases. In this report, we show our results from using NB4 cells to establish a human APL-ascites SCID mouse model, the characterization of engrafted leukemic cells, and the efficacy of chemotherapy drugs as well as ATRA in experimental therapy.

MATERIALS AND METHODS

Mice

Male and female SCID mice, 4 to 8 weeks of age, were bred and maintained under a specific pathogen-free condition in the Shanghai Institute of Materia and Medica, Chinese Academy of Sciences.

Cell Line

NB4 cells maintained in vitro were used to create the SCID mouse APL-ascites model. Before intraperitoneal inoculation (IP) into mice, NB4 cells in exponential growth were suspended in RPMI 1640 at a concentration of 1 x 10⁶/mL.

NB4 Engraftment and Serial Passage

For the first transplantation, two SCID mice were inoculated with 1 x 10⁶ NB4 cells. One month after inoculation, ascites appeared in the peritoneal cavity of the animals. Ascitic cells, 1 x 10⁶, (hereafter, A-NB4) were administered IP into each mouse for passage, and for each passage two to five mice were used.

Drug

ATRA (molecular weight [MW] 300.42) was obtained from Fumihito He Pharmaceutical Laboratory and suspended in 0.5% carboxymethyl cellulose (CMC). Adriamycin (ADM) was obtained from Farmitalia Carlo Erba SPA, Italy.

From www.bloodjournal.org by guest on October 31, 2017. For personal use only.
Characterization of A-NB4 Cells and Organ Infiltration After Nine Passages

Morphology. For morphologic evaluation, ascitic cell slides were prepared with a cytopsin (Shandon, Cheshire, UK) (10^4-10^5 cells/slide) and stained with Wright's stain. Pathologic examinations were also carried out in order to estimate the possible infiltration of A-NB4 cells in different organs.

Clonogenic assay. NB4 cells (2.5 × 10^5) and A-NB4 cells (2.5 × 10^5) from three SCID mice were plated in 24-well petri dishes with 0.5 mL 25% McCoy 5A Medium, containing 25% blast promoting activity (BPA) and 0.3% agarose. After incubation in 5% CO_2 at 37°C for 10 days, colonies (≥30 cells) were counted.

Cyto genetics. Chromosome studies were performed on NB4 cells maintained in vitro and A-NB4 cells from SCID mice using standard R banding techniques. Karyotype analysis was carried out according to ISCN criteria.

RT/PCR analysis of PML-RARα fusion mRNA. RT/PCR assay for PML-RARα was carried out with both parental NB4 and A-NB4 cells, as well as different organs of SCID mice carrying A-NB4 ascites according to the method established in our laboratory.

Immunologic staining for PML in pathology sections of different organs. Immunologic staining of pathology sections of different organs was performed using antihuman PML antibody as previously described.

Differentiation assays. NBT reduction and expression of cell surface differentiation antigens CD11b and CD33 were performed with previously described methods to measure differentiation induction.

Experimental therapy. The effect of ATRA and ADM on A-NB4 cells was studied in SCID mice during the ninth to twelfth passage. For ATRA treatment, SCID mice were inoculated with 1 × 10^6 A-NB4 cells and treated by intragastric tube at a daily dose of 25 or 50 mg/kg six times per week, or by IP injection at a dose of 5 or 10 mg/kg every other day (three times a week). The total treatment schedule was 4 weeks. Larger doses or more frequent use of ATRA were shown to be toxic to the animals (data not shown). ADM was administered IP every other day (three times a week) for 3 weeks, with a daily dose of 1 mg/kg.

RESULTS

Serial Passage of A-NB4 Cells in SCID Mice

One month after inoculation with 1 × 10^6 NB4 cells, the abdomen contained moderate ascites with numerous A-NB4 cells. The ascites containing A-NB4 cells could be engrafted through serial IP inoculations into SCID mice to produce new ascites for further passage. The A-NB4 cells grew exponentially from day 6 after transplantation and reached a quasi-stationary state by day 15 (Fig 1). The percentage of cells maintained in vitro and A-NB4 cells from SCID mice using three passages is 3 weeks with a 100% success rate of tumor induction.

Biologic Properties of A-NB4 Cells

Cells from ascites (A-NB4 cells) were similar in morphology (large size, high nuclear/cytoplasm ratio, fine chromatin
structure with visible nucleoli, basophilic cytoplasm) to NB4 cells maintained in vitro, except for the presence of a large number of vacuoles in the former. Phenotypic analysis using monoclonal antibodies against CD11b and CD33 showed that the percentage of CD11b positive A-NB4 cells (46.5% ± 10.3%) was higher than that of the NB4 cells (16.0% ± 6.0%), while the percentage of the CD33 positive A-NB4 cells (78.6% ± 13.5%) was lower than that of NB4 cells (94.3% ± 4.5%) maintained in vitro. Clonogenic cells in A-NB4 (6.3 ± 1.2/10^4 cells) was significantly lower than that of NB4 maintained in vitro (15.4 ± 0.9/10^4 cells). Cytogenetically, A-NB4 cells have the same karyotype as the original NB4 cells, which is hypotetraploid with the typical chromosome translocation t(15;17) of APL (Fig 2A and B). The long type PML-RARα transcripts, normally maintained in the NB4 cell line, was also present in A-NB4 cells (Fig 3).

Differentiation induction by ATRA was studied in A-NB4 cells. In vitro ATRA treatment of A-NB4 cells induced a significant differentiation as measured by morphologic and phenotypic parameters (data not shown). NBT reduction was increased by 9.6- to 27-fold (Fig 4A). These results were comparable with parental NB4 cells. However, the response of A-NB4 cells to in vivo ATRA treatment was relatively weak. There was no significant difference in CD11b and CD33 expression between the ATRA-treated group and the control group. The NBT reduction performed before and after two IP administrations of ATRA in the same mice showed an increment of 2.8- to 4.4-fold (Fig 4B). We also examined the differentiation status of A-NB4 cells on day 25 after transplantation in animals receiving ATRA experimental therapy IP protocol (see Materials and Methods). Most cells displayed a maturation to the myelocyte stage, but no segmented granulocytes could be observed. The NBT reduction was mildly increased (2.0- to 4.2-fold) compared with the control (Fig 4C).
Fig 3. RT/PCR of PML-RARα fusion mRNA of A-NE4 cells obtained from the APL-ascites model (mouse 1, 2, and 3) compared with in vitro cultured NB4 cells. Control RNA was from non-APL human cells. The size marker is pGEM 7Zf/HaeIII. Note that PCR products of the same size corresponding to the long type fusion transcript are seen in both ascitic A-NE4 cells and parental NB4 cells.

Therapeutic Efficacy of ATRA and ADM in APL-Ascites Model in SCID Mice

When SCID mice bearing A-NB4-ascites were treated with two doses of ATRA (5 or 10 mg/kg each time), the mean survival of these two groups was 28.1 days and 29.1 days, significantly higher than that of the control (21.6 days, \( P < .001 \)). No apparent effect was seen in the groups treated with intragastric gavage of ATRA (data not shown). On the other hand, ADM resulted in a better survival rate (44.6 ± 5.5 days) \( (P < .001 \) compared with the control group; \( P < .01 \) compared with the ATRA IP-treated group; Fig 5).

DISCUSSION

The NB4 cell line was derived from peripheral blood cells of a patient with APL during the second relapse of the disease, it has been maintained in vitro for 5 years and undergoes differentiation induction by ATRA. Heterotransplantation of these cells into nude mice was unsuccessful (Zhang and Zhu, unpublished data), necessitating the use of SCID mice as described in this work. Our study indicated that although the ascitic cells (A-NB4) share the genotypic features with the parent NB4 cell line, there were some phenotypic modifications in terms of the morphology (vacuolation), immunophenotype (altered CD11b and CD33 expression), and clonogenecity (decreased in vitro clonogenic fraction). These modifications could be caused by a selection or modulation process during the in vivo expansion of NB4 cells and perhaps also occur in the patient with APL.

Fig 4. (A) NBT reduction of A-NB4 cells obtained from three mice treated in vitro with ATRA \( (10^{-7} \text{ mol/L}) \) for 48 hours as compared with the parental NB4 cell line. (B) NBT reduction by A-NB4 cells after in vivo treatment with ATRA (IP: 10 mg/kg every other day, for a total of two times). Note that for better comparison, mice 1 and 2 were used for both in vitro (A) and in vivo (B) analysis. (C) Comparison of NBT reduction of A-NB4 cells on day 25 after inoculation in mice treated with the ATRA experimental protocol (see text) and in control group.
The survival of SCID mice with APL-ascites significantly increased as a result of ADM treatment and provides a preclinical model for the screening of chemotherapy drugs. Our data thus far shows that in vivo treatment with ATRA prolongs the survival time of A-NB4 SCID mice but does not eradicate the tumor. Indeed, the differentiation of A-NB4 cells with ATRA treatment in vivo did not appear to be profound since NBT reduction was only increased 2- to 4-fold (Fig 4, B and C). A-NB4 cells matured only to the myelocyte stage when treated with ATRA. This relatively weak differentiation is in line with the limited improvement of survival of the animals. This modest in vivo therapeutic effect may relate to the heavy burden of tumor cells present at the time of treatment or a low bioavailability of ATRA in SCID mice. A-NB4 cells were as differentiation responsive to in vitro ATRA treatment as cultured NB4 cells when measured by NBT reduction (see Fig 4A), suggesting that IP administration of ATRA may not be readily bioavailable. However, the NB4-SCID mice did respond to treatment with ATRA and may represent the first animal model demonstrating the therapeutic efficacy of differentiation induction. It is possible that a more profound effect could be obtained with a different route of administration or the use of more potent retinoids or retinoids used in combination with non-retinoid differentiation inducers, as recently described.18-20 ADM, as in patients with APL, significantly prolonged the survival of A-NB4 SCID mice. This in vivo model allows for developing combination cytotoxic-differentiation therapy, which is predicted in vitro to significantly enhance differentiation and apoptotic cell death in leukemic cells.21-23 Moreover, this animal model could also be used to address other basic or practical questions, such as the transforming ability of the PML-RARα fusion gene24-25 by blocking the expression of PML-RARα in A-NB4 cells, or the study of the mechanism of relapse after ATRA treatment.

An authentic leukemia in SCID mice would be a more ideal model than IP inoculation of A-NB4 cells in ascites. Such a model is important for studying the interaction between APL cell proliferation, infiltration, and normal hematopoiesis, as well as normal bone marrow stroma. These data would help in understanding the pathogenesis and treatment of human APL. Unfortunately, we have failed to induce leukemia in SCID mice by direct intravenous injection of cultured NB4 cells. Hematopoietic growth factors including stem cell factor and a fusion protein of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) together with irradiation allowed human AML cells to grow in vivo in hematopoietic tissues.4 Whether these additional treatments will allow NB4 cells or fresh human APL cells to proliferate in the bone marrow as well as peripheral blood in recipient SCID mice is worth further investigation.

ACKNOWLEDGMENT

We thank Q.H. Huang for RT/PCR analysis, Q. Cao and X.Y. Su for help with karyotyping the A-NB4 cells, G. Fu and P. Zhao for secretarial support, and all the members of the Shanghai Institute of Hematology for their encouragement and assistance.

REFERENCES

line in mice with severe combined immunodeficiency disease. Cancer Res 53:1392, 1992
Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice

SY Zhang, J Zhu, GQ Chen, XX Du, LJ Lu, Z Zhang, HJ Zhong, HR Chen, ZY Wang, R Berger, M Lanotte, S Waxman, Z Chen and SJ Chen

Updated information and services can be found at:
http://www.bloodjournal.org/content/87/8/3404.full.html
Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml